differentiation. Here we report a side-by-side comparison of four ITK inhibitors. We investigate effects on apoptosis, phosphorylation of signaling molecules, calcium flux and migration. In line with a specific mechanism of action ONO7790500 and BMS509744 did not inhibit MEK1/2 or AKT phosphorylation although other ITK inhibitors, ibrutinib and PF-06465469, did have this effect. Specific ITKi had modest effects on apoptosis alone but there was definite synergy with doxorubicin, pictilisib (PI3Ki) and idelalisib (PI3Kδi). ITKi repressed migration of Jurkat cells caused by CXCL12 and the CXCR4 antagonist, plerixafor enhanced this effect. Overall ITKi may have several mechanisms of action that will be therapeutically useful in PTCL including reduction in survival and perturbation of trafficking.
ITK is a tyrosine kinase expressed in AITL 29 and a chromosomal translocation involving ITK and SYK 30 is present in about 20% of follicular T-cell lymphoma 31 and is sufficient to drive lymphomagenesis in a mouse model 32 .
ITK has a structurally similar ATP binding site to that of the B-cell specific tyrosine kinase, BTK 33 and ibrutinib, a small molecule BTK inhibitor that is clinically effective in various B-cell lymphoproliferative diseases, also inhibits ITK. This has suggested that ibrutinib might find uses in treating T-cell diseases 33, 34 . Ibrutinib is currently being trialled in PTCL (clinicaltrials.gov, NCT02309580) but it is likely to reach optimal efficacy in combination with other agents, either conventional chemotherapy or novel small molecule inhibitors. Here we determine synergistic combinations with ibrutinib or ONO-7790500 a highly specific ITK inhibitor, and report potential enhancement of activity to be taken forward in further pre-clinical testing in mouse models of T-cell lymphoma.
Results

Characterisation of ONO-7790500: effects on growth, motility and cytokine production. Four
human T-cell lines were selected for study: Jurkat, MOLT4, CCRF CEM are derived from acute lymphoblastic leukaemia and K299 from a patient with anaplastic large cell lymphoma. Jurkat has been extensively used for the analysis of T-cell receptor and calcium signalling as well as cytokine production 35 . We compared four small molecule ITK inhibitors: ONO-7790500 (IC50 <4 nM), BMS-509744 (IC50 19 nM), PF-06465469 (IC50 2 nM) and ibrutinib (IC50 2.2 nM) ( Fig. 1) .
ITK protein was expressed in Jurkat, MOLT4 and CCRF CEM but was not detectable in K299 ( Fig. 2A,B ). All four of the small molecule ITK inhibitors (ITKi) reduced ITK phosphorylation although BMS509744 appeared less potent than the other inhibitors in Jurkat cells. To further characterise ITK in these cell lines we determined relative mRNA expression. Jurkat and MOLT4 had similar levels of ITK while CCRF CEM had levels about 25% of those in Jurkat and in K299 expression was undetectable ( Fig. 2C ). Of the TEC family kinases T-cell express very little TEC (~100-fold less than ITK 36 ) but RLK (~3-fold less than ITK 36 ), has been suggested to substitute for some ITK functions. Accordingly we assessed RLK mRNA levels. Compared to Jurkat and MOLT4, which had similar RLK levels, K299 had levels ~15-fold higher and CCRF CEM levels ~4-fold higher.
As an independent means of assessing ITK function in Jurkat cells we carried out siRNA knockdown (Fig. 3A ). This produced significant reduction in cell survival (two tailed unpaired t-test, P < 0.0001) ( Fig. 3B ) and effectively suppressed calcium flux (Fig. 3C ).
Comparative effects of ITKi on signalling and cytokine production. ITK is important in T-cell
receptor and downstream signaling. All four ITKi abolished phosphorylation of PLCγ, which lies immediately distal to ITK in the signaling cascade ( Fig. 4A ) but there were differential effects on MEK1/2 and AKT. The more specific ITKi, ONO7790500 and BMS509744, did not prevent phosphorylation of MEK1/2 or AKT while PF-6465469 and ibutinib did have this effect. Effects on MEK1/2 and AKT signaling might be due to off-target effects of the less specific ITKi. ITK exerts many of its effects through nuclear translocation of the transcription factor, NFATc1. We demonstrated that stimulation of Jurkat cells by anti-CD3/CD28 caused nuclear translocation of NFATc1 and this was abolished by ITK inhibitors (Fig. 4B ). Next we investigated effects of ITKi on calcium flux ( Fig. 4C ). All four inhibitors repressed calcium flux in response to anti-CD3/CD28 stimulation.
Cytokine production by T-cells is important for T-cell differentiation 37, 38 and germinal centre B-cell responses 14, 39 . We demonstrated that Jurkat cells produce IL-2 and IL-21 following PHA/PMA stimulation. IL-2 production was significantly (two-tailed unpaired t-test) repressed by ibrutinib (P = 0.0034), PF-6465469 (P = 0.002), BMS509744 (P = 0.008) and ONO7790500 (P = 0.004) and the less specific inhibitors ibrutinib (P = 0.02) and PF-6465469 (P = 0.005) produced significantly more repression than ONO7790500 or BMS509744 ( Fig. 4D ). Similarly IL-21 production was significantly (two-tailed unpaired t-test) repressed by ibrutinib (P = 0.004), PF-6465469 (P = 0.003), BMS509744 (P = 0.004) and ONO7790500 (P = 0.006) and again the less specific inhibitors ibrutinib (P = 0.03) or PF-6465469 (P = 0.008) produced significantly more repression than ONO7790500 or BMS509744 ( Fig. 4D ).
ITKi effects on viability and apoptosis.
We determined the effects of ITKi on cell line viability as measured by ATP luminescence. For all four small molecules investigated Jurkat was the most sensitive cell line while K299 was the least sensitive ( Fig. 5A ). However, differences between IC50s for survival for these two cell lines ( Fig. 5B ) were modest at between 2.5-fold for PF-6465469 and 4.6-fold for ONO7790500. This could be due to effects on RLK, the TEC family kinase that is more highly expressed in K299 ( Fig. 2C ). Western blotting showed no detectable tyrosine phosphorylation of RLK at baseline and, therefore, there was no discernible effect of ITKi on tyrosine phosphorylation suggesting either that the small molecules have other effects on RLK or off-target effects (Supplemental Fig. 1 ). In order to assess further the off-target effects on survival of ITKi we investigated the non-small cell lung cancer cell line, H460, and two B-cell lymphoma cell lines, SUDHL6 and Ramos (Fig. 5C ). All the inhibitors had IC50s >10 µM for H460 while for the B-cell lines, which express BTK, the ONO7790500 IC50 was >20 µM and BMS509744 IC50 was >10 µM while for PF-6465469 and ibrutinib IC50s were <10 µM. This suggests that ONO7790500 and BMS509744 had little activity against BTK whereas PF-6465469 and ibrutinib reduce survival through their effects on this enzyme. ATP luminescence is not a measure of apoptosis and, therefore, we directly determined apoptosis in T-cell lines due to ITKi (Fig. 5D ,E). Apoptosis at lower concentrations of ITKi (4 µM) varied from 10 to 30% across cell lines but was 40 to 93% at the highest concentration (16 µM). Apoptosis occurred in K299, a cell line without detectable ITK, to almost the same degree as the other cell lines. Analysis of PARP1 cleavage ( Fig. 5E ) confirmed that ITKi induced apoptosis with PF-6465469, one of the less selective inhibitors, appearing to be most effective. Concentration and time dependence ( Fig. 6 ) of reduction in viability was investigated in order to determine the effects of ITKi in greater detail. The kinetics of loss of viability appear to be slower for ONO7790500 with only a modest loss of viability at 24 hours although the other inhibitors almost reached their maximum effects at this time point. Secondly, the maximum loss of viability obtained with ONO7790500 at each time point is less for the K299 cell line, which has least ITK, than for the other inhibitors.
Overall the ITKi employed in this study appear to cause greater reduction in survival and induction of apoptosis in the more highly ITK expressing cell lines but the differences are quite modest. In line with the findings of others in primary human T-cells 40 , ITKi were not highly effective at inducing apoptosis. ONO7790500 appears to show the greatest specificity for ITK expressing cells in reducing survival.
Synergy with chemotherapy and PI3K inhibitors. Therefore, our studies of ITKi support the previously demonstrated key roles of this enzyme in calcium signaling and cytokine production 25,41 but while we demonstrate that the most specific inhibitors, ONO7790500 and BMS509744, have very little activity against the BTK containing B-cell lines, Ramos and SUDHL6 ( Fig. 5C ), there is only modest distinction from K299, which expresses RLK but not ITK. Therefore, we investigated synergy with the anthracycline antibiotic, doxorubicin, and small molecule phosphoinositide-3-kinase (PI3K) inhibitors as routes to maintaining efficacy but avoiding off-target effects ( Fig. 7 ). For these experiments we chose ONO7790500 and ibrutinib, which both have high affinity for ITK ( Fig. 1 ) and two cell lines, Jurkat and MOLT4. Both ITKi synergised strongly with doxorubicin with combination indices (CI) <1 at all concentrations tested ( Fig. 7A ). Similarly both a specific PI3Kδ inhibitor, idelalisib, which is employed to treat chronic lymphocytic leukaemia 42 and a non-specific inhibitor, pictilisib, which has been trialled in the treatment of breast cancer 43 enhanced the effects of ITKi.
ITKi impairs lymphocyte migration in combination with the CXCR4 antagonist, plerixafor.
Migration and invasiveness are key features of cancer 44 and regulated trafficking of lymphocytes is essential for normal immunity. A small molecule inhibitor of lymphocyte egress from secondary lymphoid organs, FYT720, has potential uses in the treatment of multiple sclerosis 45 . We investigated the combination of ITKi with plerixafor, a molecule that is employed to harvest stem cells 46 . Firstly, we demonstrated that over a dose range (0.5 to 60 nM) plerixafor did not reduce cell viability at 24 or 48 hours demonstrating that cell death is not a cause for any differences in cell migration observed over this time (Fig. 8A ). Next we demonstrated that ITKi significantly (unpaired 2-tailed t-test) inhibit migration of Jurkat cells in response to CXCL12; ONO7790500 (P = 0.01), BMS509744 (P = 0.01), ibrutinib (P = 0.02) and PF-06465469 (P = 0.03) (Fig. 8B) . The more specific ONO7790500 and BMS509744 were slightly more effective although the difference between ibrutinib/ PF-06465469 and ONO7790500/BMS509744 was not statistically significant. Plerixafor alone ( Fig. 8C ) reduced migration of Jurkat cells to CXCL12 with an EC50 of 100 nM. For synergy experiments we chose to employ plerixafor (50 nM), which alone reduced migration to 72%, in combination with a range of ITKi concentrations (Fig. 8D,E) . Plerixafor enhanced the reduction in migration due to both ibrutinib and ONO7790500 (Fig. 8D,E) . Plerixafor (50 nM) with either ibrutinib (1 µM) or ONO7790500 (0.1 µM) reduced migration to 50%. Overall the data suggests that ITK pathways are necessary for full migration of Jurkat cells in response to CXCL12 but are not sufficient. 
Discussion
In many cancers including PTCL there is a need for more effective therapies, which are also well-tolerated by patients. In addition resistance to chemotherapeutic agents is a major cause of treatment failure. The use of combination chemotherapy is a route to promoting efficacy while maintaining toxicities at tolerable levels and minimising opportunities for drug resistance. However, while there have been attempts to produce rational combinations with small molecule inhibitors 47 there is at present no standard route to achieving this result.
There has been intense interest in Tfh signalling pathways since the discovery of the critical role of this subset in normal immunity 48 . Several surface molecules are targets for therapeutic antibodies. For example anti-PD-1 antibodies have been trialled in solid cancers 49 and T-cell lymphomas 50 and anti-ICOS antibodies are being investigated in the auto-immune condition, systemic lupus erythematosus 51 as well as PTCL (clinicaltrials.gov identifier NCT02520791).
PI3K has a key role in Tfh cells 48 . Specifically the function of the isoform PI3Kδ has been investigated in T-cells in mice expressing catalytically inactive p110δ. T-cells in these animals demonstrated a failure of trafficking in response to T-cell receptor stimuli and subsequent failure of inflammation 52 . Further evidence for a specific PI3K role in T-cells comes from studies in which PI3Kδ was conditionally deleted from T-or B-cells 53 . PI3Kδ was required for formation of Tfh cells and specifically signalling from the surface protein, ICOS. Small molecule PI3Kδ inhibitors have entered clinical practice for the treatment of chronic lymphocytic leukaemia 42, 54, 55 . Overall inhibition of PI3K could be a strategy for T cell diseases.
The tumour microenvironment i.e. non-malignant stromal cells or lymphocytes and associated secreted growth factors and chemokines. supports proliferation and resistance to conventional chemotherapy in the B-cell lymphoproliferative disorders chronic lymphocytic leukaemia 56 and follicular lymphoma 57 . The microenvironment is also likely to be important in peripheral T-cell lymphomas 58 . The G-protein coupled chemokine receptor, CXCR4, is highly expressed on normal germinal centre Tfh cells 59 . CXCR4 is associated with clinical outcome in acute myeloid leukaemia 60, 61 and melanoma 62 demonstrating a wide biological role for CXCL12/CXCR4 signalling. Interruption of CXCR4 signaling by several methodologies has been suggested as a route to therapy [63] [64] [65] . More recently the farnesyl transferase inhibitor, tipifarnib, has been postulated to interrupt CXCL12/CXCR4 signalling in AITL 66 . Therefore, interruption of cell trafficking by disrupting CXCR4 signalling from the tumour microenvironment is a potential therapy in PTCL.
ITK is activated by CXCR4 in a PI3K dependent manner 22 and it has been suggested that ITK inhibitors might be useful agents in vivo to perturb migration and could enhance the effects of cytotoxic chemotherapy. In this report we found that plerixafor, a CXCR4 antagonist already in clinical practice for mobilisation of stem cells prior to high dose therapy, enhanced the effects of ITK inhibitors in repressing migration of Jurkat T-cells while not having an effect on cell survival. An intriguing possibility is that adding Plerixafor and an ITK inhibitor to current regimens might enhance effectiveness by perturbing normal cell trafficking. Inhibition of lymphocyte migration is a target for therapy in the autoimmune condition multiple sclerosis 45 . Invasiveness is also a hallmark of cancer 44 . We postulate that disruption of lymphocyte trafficking will be an adjunct to current treatments for T-cell lymphoma.
We sought synergistic combinations with ITKi, which might have therapeutic usefulness. CHOP chemotherapy (of which the constituents are doxorubicin, cyclophosphamide, vincristine and prednisolone) is one of the standard treatment regimens for PTCL but therapeutic responses are not adequate or durable 4, 67 . Our study demonstrated synergy between ITKi and doxorubicin. The PI3Kδi, idelalisib, is in clinical use for chronic lymphocytic leukemia 42 . We showed synergy between idelalisib or pictalisib, a non-specific PI3K inhibitor, and ITKi. Cell migration has not been a target for therapy but it is intriguing that plerixafor enhances the loss of migration caused by ONO7790500 or ibrutinib.
In summary, the combination of ITK inhibitors and some chemotherapeutic agents led to impressive effects in vitro. We suggest that ITK inhibitors might usefully be added to chemotherapy regimens for the treatment of some types of PTCL. Based on our preclinical results, validation of drug combination synergy between ITK inhibitors and conventional chemotherapies employed in this study needs to be assessed in animal models of lymphoma. 
Materials and Methods
Cell lines and cell culture. Jurkat, MOLT-4, K299 and Ramos were maintained in RPMI-1640 (Invitrogen, Thermo Fisher Scientific, Waltham, MA, USA) with 10% fetal calf serum (FCS) (Lonza, Basel, Switzerland) and penicillin (10,000 units/ml) (Lonza) and streptomycin (10,000 g/ml) (Lonza) at 37 °C and 5% CO 2 . CCRF CEM cells were cultured in RPMI-1640 medium containing 20% FCS and penicillin (10,000 units/ml) (Lonza) and streptomycin (10,000 g/ml) (Lonza). HEK293 cells were maintained in DMEM medium (Invitrogen) and 10% FCS. CellTiter-Glo ® (CTG) luminescent cell viability assay (Promega, Madison, WI, USA). Briefly, CTG reagent (100 μl) was added to 100 μl of cell suspension in a 96-well plate. After mixing on an orbital shaker to induce cell lysis for 2 minutes the plate was incubated at room temperature for a further 10 minutes. Luminescence readings were determined using the Wallac VICTOR 2 Multilabel Counter (PerkinElmer, Beaconsfield, UK).
Apoptosis was determined using a FITC Annexin V Apoptosis Detection kit I (BD Biosciences, Wokingham, UK) and Draq7 ™ (BioLegend, San Diego, CA, USA). Cells were treated with ITK inhibitors at the indicated concentrations for 24 hours and pellets were harvested at 200 g for 5 minutes at room temperature, washed twice with cold PBS before resuspending in annexin binding buffer (100 µl) with annexin-V (5 µl) and Draq7 (1 µl). The cells were incubated for a further 20 minutes at room temperature before adding annexin binding buffer (400 µl) and
incubating on ice. Data was acquired and analysed on a FACSCanto ™ II ((BD Biosciences).
Analysis of drug combinations.
Jurkat cells were treated with five concentrations of the combination for 48 hours at 37 °C. The concentration ranges of drugs were based on the IC50 of these drugs. The anti-tumor activities of PF-06465469 or Ibrutinib in combination with Cyclosporine A (S2286, Sigma), Romidepsin (S3020, Sigma), Pralatrexate (S1497, Sigma), Gemcitabine (S1714, Sigma), Pictilisib (S1065, Sigma) and Doxorubicin (44583, Sigma) were assayed in 96-well plates. The fractional affected (Fa) was calculated from the percentage growth inhibition by the formula Fa = 1 − (% growth/100). The Fa values were entered separately into Calcusyn (Biosoft, Cambridge, UK) analysis program for single agents and combinations. This method provides quantification of synergy (combination index, CI <1) or antagonism (CI >1) at different dose and effect levels.
Calcium flux assay. Intracellular calcium mobilisation was detected with FluoForte Calcium Assay Kit (ENZ-51016, Enzo Life Sciences, Farmingdale, NY, USA). Jurkat cells (1.25 × 10 5 cells/ml) were treated with ITK inhibitors at concentrations around the IC50 for growth for 4 hours at 37 °C. Cells were centrifuged at 800 g for 2 minutes and the pellets re-suspended in FluoForte dye-loading solution, and plated in 96-well black tissue culture plates (655086, Greiner). Cell plates were incubated for 45 minutes at 37 °C and then for 15 minutes at room temperature before activating by adding Dynabeads ™ Human T-Activator anti-CD3/CD28 beads (Gibco, Thermo Fisher Scientific, Waltham, MA, USA). At the end of the experiment ionomycin (1 µg) (I3909, Sigma) was added to ensure maximal calcium mobilisation. Fluorescence was measured at excitation = 490 nm/emission = 525 nm with an Infinite M200 PRO (Tecan, Männedorf, Switzerland).
RT-PCR.
Total mRNA was extracted from harvested cells using a RNeasy Mini Kit (74104, Qiagen, Hilden, Germany). Reverse transcription (RT) was carried out with the SensiFAST TM cDNA synthesis kit using the manufacturer's protocol (Bioline, London, UK). A 20 µl RT reaction included 50 ng of total RNA, 5x TransAmp buffer (4 µl), reverse transcriptase (1 µl) and DNase/RNase free-water up to 20 µl. Taqman primers for ITK (Hs00950634_m1), RLK (Hs00177433_m1) and HPRT (Hs02800695) were purchased from Applied Biosystems (Foster City, CA, USA).
Western blot analysis. Jurkat, K299, CCRF CEM and MOLT-4 cell lines were lysed with radioimmunoprecipitation-RIPA buffer (Tris-HCl pH 8.0 (50 mM), NaCl (150 mM) 1% sodium deoxycholate, and 0.1% SDS) supplemented with protease and phosphatase inhibitors (Sigma). Total cell lysates were incubated on ice for 10 to 15 minutes and centrifuged at 15,000 × g for 10 minutes at 4 °C to remove debris. Bicinchoninic acid (BCA) assay (Sigma) was used to quantify protein concentration.
For cytoplasmic lysates, Jurkat cells were resuspended in lysis buffer (Hepes pH 7.6 (20 mM), 20% glycerol, NaCl (10 mM), MgCl 2 (1.5 mM), EDTA (0.2 mM), 0.1% TritonX-100, acetone (1 mM), DTT (1 mM) and orthovanadate (2 mM) along with the protease inhibitor cocktail (ab201111, Abcam)) and incubated with rotation at 4 °C for 15 minutes. The nuclei were pelleted (400 g at 4 °C for 10 minutes), resuspended in nuclear extraction buffer (Hepes pH 7.6 (20 mM), 20% glycerol, NaCl (250 mM), MgCl 2 (1.5 mM), EDTA (0.2 mM), 0.1% TritonX-100, acetone (1 mM), DTT (1 mM) and orthovanadate (2 mM) with the protease inhibitor cocktail (ab201111, abcam)), and incubated with rotation at 4 °C for 1 hour. Nuclear extracts were collected by centrifugation at 16000 g at 4 °C for 10 minutes.
Lysates were separated by SDS-PAGE on 7.5% Mini-protean TGX Precast gels (BioRad, Hercules, CA, USA), and transferred to a polyvinyldine difluoride membrane (Mini Format, 0.2 µM PVDF Single Application, BioRad). The blot was incubated in TBST (Tris-HCl pH 7.6 (20 mM), NaCl (136 mM), and 0.1% Tween-20) supplemented with 5% skimmed milk (Oxoid, Thermo Fisher Scientific, Waltham, MA, USA) for 1 hour at room temperature. The membrane was incubated with primary antibody in blocking solution at 4 °C overnight. Primary antibodies used (all at 1:1000 unless otherwise stated) were anti-ITK (ab32039, Abcam, Cambridge, UK), anti-phospho-BTK/ITK (14-9015-82, eBioscience, San Diego, CA, USA), anti-PLCγ1 (#5690, Cell Signaling Technology, Danvers, MA, USA), anti-phospho-PLCγ1 (#2821, Cell Signaling Technology), anti-AKT (#4691, Cell Signaling Technology), anti-phospho-AKT (#4060, Cell Signaling Technology), anti-MEK (#8727, Cell Signaling Technology). anti-phospho-MEK (#9154, Cell Signaling Technology) and anti-NFAT2 (NFATc) (1 µg/ml) (ab2796, Abcam). Loading control was anti-GAPDH (1:10000) (#2118, Cell Signaling Technology). Secondary antibodies used were anti-mouse-IgG-HRP conjugated (1:2000) (#7076, Cell Signaling Technology) or anti-rabbit-IgG-HRP conjugated (1:2000) (#7074, Cell Signaling Technology).
After 3 to 5 washes with TBST, the blot was incubated with secondary antibody with shaking for 1 hour at room temperature. Blots were washed five times for 10 minutes, and signal was detected with chemiluminescent HRP substrate (BioRad) and imaged (SRX-101A X-Ray Film Processor, Konica Minolta, Bloxham Mill, UK) using medical X-ray film (Fujifilm, Tokyo, Japan).
To investigate RLK in K299 we used anti-RLK antibody (ab37818, Abcam) and anti-phospho-tyrosine antibody (4g10) (#9411, Cell Signaling Technology). Following incubation with both anti-mouse IgG (926-32212, LICOR Biosciences) and anti-rabbit IgG (#5366, Cell Signaling Technology) secondary antibodies at 1:10000 for 1 hour at room temperature fluorescence was detected using a LICOR-Odyssey machine (LICOR Biosciences, Lincoln, NE, USA).
Chemotaxis Assay.
A 24-well transwell chamber with polycarbonate membrane (5 µm) (catalog no. 3421;
Costar, Kennebunk, ME, USA) was pre-coated with fibronectin (10 µg/ml) (F1141-1MG, Sigma-Aldrich). Jurkat cells were pretreated with ITK inhibitors (2 µM) for 24 hours in serum-free RPMI 1640 media. Chemotaxis medium (RPMI 1640 medium containing 25 mM HEPES buffer and 1% BSA) with and without CXCL12 (100 ng/ml) (350-NS-010, R&D Systems, Minneapolis, MN, USA) was added to the lower chamber with ITKi. Jurkat cell suspension (10 6 cells in 100 µl) were placed in the upper wells. The cells were allowed to migrate for 3 hours at 37 °C. Migrated cells were collected in the lower compartment stained with trypan blue (BioRad) and counted by hemocytometer or automated cell counter.
Statistics.
Statistical analyses were undertaken using the GraphPad Prism version 7.00 (GraphPad Software, San Diego, CA, USA). Differences were considered to be significant when P < 0·05.
